The Medicines Patent Pool (MPP) was honoured to present its Strategy 2023-2025 on Monday 30 January 2023. Since 2010, MPP has signed 34 licences for different health technologies and facilitated access to over 30 billion doses of treatments. Over the next three years, MPP will aim to conclude licences for ten innovative health products and support the introduction of affordable versions of five products that will help to improve the standard of care in LMICs across the different diseases in which MPP works. We will also support technology transfer of mRNA vaccine technology to ten manufacturers. We expect that our licences will allow 30 million people to benefit annually, double from where it stands today and contribute to saving USD 1.2 billion.


Welcome and introduction

  • Marie-Paule Kieny, Chair of the MPP Governance Board
  • Charles Gore, Executive Director, MPP
  • Lav​ Agarwal, Additional Secretary at ​the Ministry of Health and Family Welfare of the Government of India

Panel discussion 1 –  
Goal 1: Expand access to innovative medicines for infectious diseases
Goal 2:
Establish voluntary licensing as an impactful access mechanism for other diseases and conditions

  • Philippe Duneton, Executive Director, Unitaid
  • Helen McDowell, Head of Government Affairs & Global Public Health, ViiV Healthcare
  • Denise Uzoma Ejoh, Chief Executive of Cormode Cancer Foundation, Nigeria
  • Cary Adams, Chief Executive Officer, Union for International Cancer Control

Panel discussion 2 – 
Goal 3: Facilitate development and access to novel medical technologies
Goal 4:
Accelerate equitable access to countermeasures for pandemics and other international health   emergencies 
Goal 5:
Support diversified and sustainable  manufacturing capacity

  • Nombeko Mpongo, Community Liaison Administrator, Desmond Tutu Health Foundation
  • Jay Iyer, Chief Executive Officer, Access to Medicine Foundation
  • Rahul Lande, Vice President, International Business, Hetero
  • Martin Friede, Coordinator, Initiative for Vaccine Research, World Health Organization

Closing remarks

  • Erika Placella, Head of Health, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation